HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Corcept Therapeutics (NASDAQ:CORT) and raises the price target from $38 to $40.
May 02, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Corcept Therapeutics and increases the price target to $40.
The upgrade in the price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong conviction in the company's future performance. This endorsement can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100